A Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64264681 in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 04 Feb 2019
At a glance
- Drugs JNJ 64264681 (Primary)
- Indications Cancer; Immunological disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 24 Jan 2019 Planned number of patients changed from 99 to 107.
- 12 Aug 2018 Planned End Date changed from 20 May 2019 to 5 Aug 2019.
- 12 Aug 2018 Planned primary completion date changed from 20 May 2019 to 5 Aug 2019.